Emergent Biosolutions studies intranasal naloxone for opioid overdose response

Emergent Biosolutions studies intranasal naloxone for opioid overdose response
Emergent Biosolutions opioid study

Emergent Biosolutions has published research in Clinical and Translational Science evaluating the safety and pharmacokinetics of multiple-dose intranasal naloxone.

The findings contribute important evidence to inform future opioid overdose response strategies. The company continues to advance its research efforts to address opioid-related emergencies.

Emergent Biosolutions previously received a contract modification worth $64.5 million from ASPR to expand supply of botulism antitoxin. The company has emphasized its commitment to global community safety through scientific rigor and quality-driven partnerships. These efforts parallel its ongoing research into responses for opioid-related emergencies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.